Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors
Overview
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer. PURPOSE: This research trial is studying genes in tumor samples from younger patients with ovarian or testicular sex cord stromal tumors.
Full Title of Study: “DICER1 Mutations and miRNA in Ovarian and Testicular Sex Cord Stromal Tumors of Childhood”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: July 2016
Detailed Description
OBJECTIVES: – To assess the role of DICER1 mutations and miRNA pathways in the etiology and progression of ovarian or testicular sex cord stromal tumors. OUTLINE: Archived tumor tissue samples are analyzed for D1CER1 mutation and mRNA expression by reverse-transcriptase polymerase chain reaction (RT-PCR) and laser micro dissector. Results are then correlated with medical data, including age at diagnosis, diagnosis, pathology report, presenting symptoms, family history, treatment, outcome, and length of follow-up, when available.
Interventions
- Genetic: RNA analysis
- Genetic: gene expression analysis
- Genetic: mutation analysis
- Genetic: reverse transcriptase-polymerase chain reaction
- Other: laboratory biomarker analysis
- Other: medical chart review
Clinical Trial Outcome Measures
Primary Measures
- Correlation between DICER1 mutations and miRNA pathways with outcomes using descriptive analysis
Participating in This Clinical Trial
DISEASE CHARACTERISTICS:
- Fixed and frozen tissue samples from the ATBR01 B1 tissue bank and from the International Pleuropulmonary Blastoma Registry, Children's Hospital of Boston, and Massachusetts General Hospital – Tissue samples from patients diagnosed with: – Ovarian – Sertoli-Leydig cell tumor – Juvenile granulosa cell tumor – Adult granulosa cell tumor – Gynandroblastoma – Sex cord stromal tumor with annular tubules – Sex cord stromal tumor, undifferentiated – Sertoli tumor – Leydig tumor – Testicular: – Granulosa cell tumor – Sertoli tumor – Leydig tumor – Sertoli-Leydig – Undifferentiated stromal tumor PATIENT CHARACTERISTICS: – Not specified PRIOR CONCURRENT THERAPY: – Not specified
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: 120 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Children’s Oncology Group
- Collaborator
- National Cancer Institute (NCI)
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Dana A. Hill, MD, Principal Investigator, Children’s National Research Institute
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.